Premium
Enhancing engraftment of cord blood cells via insight into the biology of stem/progenitor cell function
Author(s) -
Broxmeyer Hal E.
Publication year - 2012
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2012.06509.x
Subject(s) - progenitor cell , stem cell , haematopoiesis , cord blood , transplantation , cancer research , microbiology and biotechnology , pi3k/akt/mtor pathway , biology , immunology , medicine , signal transduction
Cord blood (CB) transplantation has been used over the last 24 years to treat patients with malignant and nonmalignant disorders. CB has its advantages and disadvantages compared with other sources of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) for transplantation. More knowledge of the cytokines and intracellular signaling molecules regulating HSCs and HPCs could be used to modulate these regulators for clinical benefit. This review provides information about the general field of CB transplantation and about studies from the author's laboratory that focus on regulation of HSCs and HPCs by CD26/DPPIV, SDF‐1/CXCL12, the Rheb2‐mTOR pathway, SIRT1, DEK, cyclin‐dependent kinase inhibitors, and cytokines/growth factors. Cryopreservation of CB HSCs and HPCs is also briefly discussed.